NAD+ and NADH for ME/CFS: What the Trials Actually Show
Oral NADH and CoQ10 plus NADH have been tested in ME/CFS, with mixed results. Understand the null trials, within-group changes, and limits for IV NAD+.
Updated
5 min read · 11 sources
On this page
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is defined by exactly the kind of symptom — profound, unrelenting fatigue with post-exertional crashes — that an "energy molecule" like NAD+ seems built to fix. Unsurprisingly, NAD+ drips, NMN, and NADH supplements are all marketed to people with ME/CFS. What sets this condition apart from most NAD+ marketing, though, is that one form of the molecule — oral NADH, the reduced form of NAD+ — has actually been run through placebo-controlled trials in ME/CFS patients, some of them dating back decades. So instead of pure mechanism, there is real (if modest) human data to weigh.
This page is the honest version: why NAD+/NADH is even a candidate, what the oral NADH trials and the larger CoQ10+NADH study actually found, and why "it's been tested" is still a long way from "it works." (We cover the closely related question of NAD+ for long COVID — which often overlaps with ME/CFS — separately in our NAD+ for long COVID review; this page focuses on the ME/CFS-specific NADH trials.)
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
RxSpan MD
Physician-led NAD+ & longevity telehealth
See RxSpan MDSome fatigue studies concern the reduced form rather than an infusion: NADH versus NAD+ explains why those results cannot be transferred between products.
Why NADH is even a candidate in ME/CFS
NAD+ (nicotinamide adenine dinucleotide) and its reduced partner NADH shuttle electrons through the reactions that turn food into ATP — the cell's energy currency. If a disease is fundamentally a problem of cellular energy production, propping up this pathway is an obvious thing to try. And ME/CFS does carry biochemical fingerprints that point this way: NAD+ falls with age and metabolic stress in human tissue 1, NAD+ sits at the center of the energy and repair machinery that struggles in fatigue states 2, and a dedicated review has mapped how the kynurenine pathway — the route the body uses to build NAD+ from tryptophan — appears disturbed in ME/CFS specifically 3. So the rationale is genuinely mechanism-based, not invented.
The ME/CFS rationale
Disturbed NAD+ / kynurenine metabolism
Mapped in ME/CFS — the pathway that builds NAD+ from tryptophan
Supply oral NADH
Reduced form of NAD+; central to making cellular energy
Hoped-for: less fatigue
Seen in a subset in small trials — not a proven cure
The catch is the one that haunts the entire NAD+ field: a plausible pathway is not a proven therapy. Here, at least, we don't have to argue from mechanism alone — we have trials.
The oral NADH trials: small, old, and mixed
The anchor study is a 1999 placebo-controlled crossover trial by Forsyth and colleagues, which gave 26 ME/CFS patients 10 mg of oral NADH (or placebo) daily for four weeks each 4. It reported that roughly 31% of patients improved on NADH versus about 8% on placebo — a positive signal that launched NADH's reputation in this space. But read it honestly: it was a small, short crossover study, the response was defined on a self-reported symptom score, and even the responders represented a minority. It is a hypothesis-generating result, not a definitive one.
A 2004 randomized comparison by Santaella and colleagues tested NADH against conventional therapy rather than a matched placebo. It reported an early symptom difference that did not persist across later assessments 5. The lack of a matched placebo and substantial attrition make that early result difficult to interpret as durable efficacy.
A larger 2010 double-blind trial enrolled 86 people, with 77 completing the study, and compared 20 mg/day NADH with placebo during two months of treatment. Most clinical outcomes and overall functional performance did not improve; anxiety and maximum exercise heart rate were the limited signals reported 11. That mostly negative trial matters: the evidence is not simply two encouraging small studies awaiting confirmation.
Strength of evidence
- CoQ10 + NADH → fatigue / quality of lifeWeak evidence
Mixed trials; larger study's fatigue improvements were within-group.
- Oral NADH alone → symptom improvementWeak evidence
Small positive pilot; 2010 trial did not improve most outcomes or overall function.
- IV NAD+ → ME/CFS outcomesNone evidence
No established randomized outcome evidence.
- NMN → ME/CFS fatigueNone evidence
No established controlled clinical benefit.
The stronger study tested a combination, not NADH alone
The 2021 double-blind study randomized 207 people to CoQ10 (200 mg) plus NADH (20 mg) or placebo. The schedule was eight weeks taking the tablets and four weeks of follow-up after stopping, rather than twelve weeks of continuous supplementation. Only 144 participants completed the final assessment 6.
The distinction between comparisons changes the conclusion. Cognitive fatigue and some quality-of-life scores improved relative to the active group's own baseline. However, the published table did not show significant between-group differences in total or cognitive fatigue. At eight weeks, the total fatigue comparison had p = 0.435 6. A statistically significant change inside one group does not show that its change exceeded placebo.
An earlier eight-week combination study reported reduced maximum exercise heart rate and a fatigue signal 7. A lower peak heart rate is not, by itself, evidence of restored activity or recovery from post-exertional malaise. Both trials test two ingredients, so they cannot isolate NADH. The overall trial literature remains heterogeneous 8.
What this is NOT: IV NAD+ and NMN for ME/CFS
Notice what's missing from all of the above. The trials use oral NADH, usually combined with CoQ10. They are not trials of intravenous NAD+ drips, and they are not trials of NMN — the two most aggressively marketed (and most expensive) options. There are no randomized outcome trials of IV NAD+ for ME/CFS, and NMN has not been shown to relieve ME/CFS fatigue in controlled studies. Extrapolating the modest oral-NADH/CoQ10 signal to justify a costly NAD+ IV is exactly the kind of leap the marketing makes and the data don't support.
That caution is reinforced by the broader NAD+ precursor literature, where raising the biomarker reliably fails to translate into felt benefit. Nicotinamide riboside raised NAD+ in older adults with mild cognitive impairment without improving cognition 9, and a meta-analysis of NAD+ precursors on metabolic-syndrome parameters found benefits limited and inconsistent despite reliably elevated NAD+ 10. "Higher NAD+" is simply not the same claim as "less fatigue." We unpack that gap in our pillar guide to NAD+ therapy evidence and in does NAD+ actually boost energy.
An honest bottom line for patients
- The mechanism is plausible: ME/CFS shows disturbances in NAD+/kynurenine metabolism 3, and NAD+ is central to cellular energy 12.
- Oral NADH results are mixed: a 26-person pilot reported responders, but the larger 2010 trial found no improvement in most clinical outcomes or overall function 4511.
- CoQ10 + NADH has more randomized testing, but the 207-person study's fatigue changes were within-group, not significant advantages over placebo 6. An earlier trial's limited signals do not establish recovery 78.
- IV NAD+ and NMN have no ME/CFS outcome trials, and precursors broadly raise NAD+ without reliably improving how people feel 910.
The fair reading: oral NADH and CoQ10 plus NADH remain unproven treatments for ME/CFS. The studies do not justify promising fatigue relief or buying an expensive drip. If you're exploring it, do so with the clinician managing your condition, and start by understanding the whole field — see our NAD+ therapy evidence pillar, check the side effects of any precursor first, and see how products and providers compare on our NAD+ rankings hub.
Frequently asked questions
Does NADH help with ME/CFS fatigue?
The evidence is mixed and does not establish reliable relief. A 26-person pilot reported more responders on NADH, but a larger 2010 placebo-controlled trial found no improvement in most clinical outcomes or overall function. CoQ10 plus NADH studies cannot isolate NADH, and the 207-person study's fatigue improvements were within-group rather than significant advantages over placebo.
Is IV NAD+ proven for ME/CFS?
No. The ME/CFS trials used oral NADH (often with CoQ10), not intravenous NAD+ drips. There are no randomized outcome trials of IV NAD+ for ME/CFS. The marketing extrapolates from oral-NADH studies and from NAD+'s role in energy metabolism, but that leap is not supported by controlled human data on the IV route.
Should I take NADH or CoQ10 plus NADH for ME/CFS?
Discuss the uncertain benefit, cost, tolerability and your other medicines with the clinician managing your condition. The larger combination study used 200 mg CoQ10 plus 20 mg NADH for eight weeks, followed by four weeks off treatment. That is a research regimen, not an established ME/CFS treatment recommendation.
What is the difference between NAD+ and NADH?
NADH is the reduced form of NAD+ — the two interconvert as cells shuttle electrons through energy metabolism. The ME/CFS trials specifically used oral NADH, whereas most anti-aging NAD+ products supply precursors like NMN or nicotinamide riboside that the body converts toward NAD+. They are related but not interchangeable, and only oral NADH has the ME/CFS trial data behind it.
References
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. https://pubmed.ncbi.nlm.nih.gov/22848760/
- Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
- Dehhaghi M, Panahi HKS, Kavyani B, et al. (2022). The Role of Kynurenine Pathway and NAD+ Metabolism in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Aging and Disease. https://pubmed.ncbi.nlm.nih.gov/35656104/
- Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA (1999). Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Annals of Allergy, Asthma & Immunology. https://pubmed.ncbi.nlm.nih.gov/10071523/
- Santaella ML, Font I, Disdier OM (2004). Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. Puerto Rico Health Sciences Journal. https://pubmed.ncbi.nlm.nih.gov/15377055/
- Castro-Marrero J, Segundo MJ, Lacasa M, et al. (2021). Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. https://pubmed.ncbi.nlm.nih.gov/34444817/
- Castro-Marrero J, Sáez-Francàs N, Segundo MJ, et al. (2016). Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial. Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/26212172/
- Kim DY, Lee JS, Son CG (2020). Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Journal of Translational Medicine. https://pubmed.ncbi.nlm.nih.gov/31906979/
- Orr ME, Kotkowski E, Ramirez P, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. https://pubmed.ncbi.nlm.nih.gov/37994989/
- Oliveira-Cruz A, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
- Alegre J, Rosés JM, Javierre C, Ruiz-Baqués A, Segundo MJ, Fernández de Sevilla T (2010). Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Revista Clínica Española. https://pubmed.ncbi.nlm.nih.gov/20447621/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NAD+ and Lupus: NR Trials, Skin Studies and Evidence Limits
NR is being studied in lupus, while niacinamide has separate skin research. Understand the human evidence, ongoing trial and limits for systemic disease.
ReadNicotinamide Riboside (NR) Dosage: What the Trials Used
NR studies have tested 100–3,000 mg/day in different populations and timeframes. Compare the doses, safety limits and why trial dosing is not personal advice.
ReadNAD+ and NMN for Hair Growth: What the Studies Tested
Hair-growth research on NMN, NAD+ and topical blends: what mice, follicle cells and human studies do—and do not—show about regrowth.
ReadNAD+ for Brain Fog: What Human Cognition Trials Show
Does NAD+ help brain fog? Compare oral NR cognition trials with claims for injections, and distinguish brain fog from MCI and dementia.
ReadNAD+ for Men: Energy, Muscle and Testosterone Evidence
What NAD+ precursor trials in older men show about muscle and function—and why testosterone, ED and fertility claims need different evidence.
ReadNAD+ With Semaglutide or Tirzepatide: What Is Known
NAD+ is sold alongside GLP-1 medicines, but added benefit is unproven. Understand separate prescriptions, mixed formulations and what to ask.
Read